Produktname:5-((4-ethylpiperazin-1-yl)methyl)pyridin-2-amine
IUPAC Name:5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-amine
- CAS：1180132-17-5
- Molekulare Formel：C12H20N4
- Reinheit：95%
- Katalognummer：CM169616
- Molekulargewicht：220.32
Nur für den Einsatz in Forschung und Entwicklung..
Produkt-Details
- CAS-Nr.:1180132-17-5
- Molekulare Formel:C12H20N4
- Schmelzpunkt:-
- SMILES-Code:CCN1CCN(CC2=CN=C(N)C=C2)CC1
- Dichte:
- Katalognummer:CM169616
- Molekulargewicht:220.32
- Siedepunkt:362°C at 760 mmHg
- Mdl-Nr.:MFCD14706690
- Lagerung:Keep in dark place, store at 2-8°C.
Category Infos
- Piperazines
- Piperazine is an organic compound consisting of a six-membered ring containing two nitrogen atoms in opposite positions in the ring. The chemical formula of piperazine is C4H10N2, and it is an important pharmaceutical intermediate. Pyrimidines and piperazines are known to be the backbone of many bulk compounds and important core structures for approved drugs; studies have shown that combining a pyridine ring with a piperazine moiety within a single structural framework enhances biological activity.
- Pyridines
- Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.
- Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu
- Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer
- Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.
Column Infos
- Abemaciclib
- Lilly announced the five-year results of a pre-planned analysis of Phase 3 MonarchE study, which evaluated two years of adjuvant Verzenio® (Abemaciclib) in combination with endocrine therapy (ET) compared with ET alone in patients with HR+, HER2-, node-positive early breast cancer (EBC) at a high risk of recurrence. Abemaciclib is the first and only CDK4/6 inhibitor approved for the treatment of node-positive, high-risk early breast cancer (EBC) patients.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.
Suche 
+86 21 5895 0110 
